Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emiplacel - Pluristem

Drug Profile

Emiplacel - Pluristem

Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; PLacental eXpanded cells; PLX PAD; PLX-PAD cell therapy

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pluristem Therapeutics
  • Class Ischaemic heart disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia; Thromboangiitis obliterans
  • New Molecular Entity No

Highest Development Phases

  • Phase III Muscle injury; Peripheral arterial disorders
  • Phase II Intermittent claudication
  • Clinical Phase Unknown Thromboangiitis obliterans
  • Preclinical Duchenne muscular dystrophy; Graft-versus-host disease
  • No development reported Ischaemic heart disorders; Preeclampsia; Pulmonary arterial hypertension; Tendon injuries

Most Recent Events

  • 09 Jan 2019 Case study efficacy data from compassionate use treatment in Thromboangiitis obliterans released by Pluristem Therapeutics
  • 09 Jan 2019 Pluristem Therapeutics plans an Expanded Access Program for Thromboangiitis obliterans
  • 20 Nov 2018 WideTrial initiates an expanded-access programme for Peripheral arterial disorder in USA (NCT03746899)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top